Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-escalation study of [90Y]Y-PentixaTher in recurrent or refractory CNS lymphoma
2024-512097-98-00Phase 2Completed
- Sponsor
- Pentixapharm
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 90Y-Pentixather in central nervous system lymphoma, primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Pentixapharm. Primary endpoints: Incidence, severity and relationship of adverse events and serious adverse events, Incidence and severity of dose-limiting toxicity and 6 more. Started Nov 2023; status: completed.
02
Drugs
90Y-Pentixather
03
Conditions
central nervous system lymphomaprimary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on 2024-512097-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512097-98-00.